Home » French Pharma Groups Face Traumatic Blows
French Pharma Groups Face Traumatic Blows
When French authorities stopped reimbursing Multaq, a treatment for irregular heartbeat, late last year, it was more than just a blow to the country’s flagship pharmaceutical group. It signaled that the pressure on the French industry was more intense than in many other European states.
Financial Times
Financial Times
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May